Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTX-463 in Idiopathic Pulmonary Fibrosis (IPF)
NCT06967805Phase 2Active, not recruiting
- Sponsor
- Mediar Therapeutics
- Start
- May 2025
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing MTX-463 with Placebo (2 arms). Primary endpoint: Forced Vital Capacity at 24 weeks. Started May 2025; status: active, not recruiting.
02
Drugs
MTX-463
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06967805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06967805.